Austin, July 16, 2025 (GLOBE NEWSWIRE) -- Psoriatic Arthritis Treatment Market Size & Growth Analysis:
According to SNS Insider, the global Psoriatic Arthritis Treatment Market was valued at USD 11.08 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 9.70%, reaching USD 25.41 billion by 2032.
The psoriatic arthritis treatment market is displaying strong growth on account of the rising prevalence of psoriatic diseases, growing awareness, and developments in biologic and targeted therapies. A favorable reimbursement landscape and increasing interest in personalization play a role in driving the growth. Moreover, the emergence of novel pipeline drugs and rising healthcare spending, particularly in developing regions, will further drive the demand in the forecast years.
Request Your Free Sample Copy of the Psoriatic Arthritis Treatment Market Report Today: https://www.snsinsider.com/sample-request/3223
The U.S. psoriatic arthritis treatment market was estimated at USD 3.33 billion in 2023 and is expected to reach USD 7.36 billion by 2032, at a CAGR of 9.24% during the forecast period of 2024-2032
The North American psoriatic arthritis treatment market is led by the U.S. owing to higher advances in health care facilities, a high rate of adoption of biologics, and favorable reimbursement policies. Furthermore, potent R&D activity and early access to new therapies continue to support its status as a leading regional player.
By Drug Class, the Biologics Segment to Dominate the Psoriatic arthritis treatment Market
The biologics segment dominated the market dominated the psoriatic arthritis treatment market with a 31.54% market share in 2023, owing to their better efficacy in the treatment of moderate-to-severe disease, faster onset of action, and their targeted mode of action, which reduces the systemic adverse effects. There is now strong evidence of clinical efficacy and patient response to biologic agents (TNF inhibitors and IL-17/IL-23 inhibitors), which have emerged as the preferred option in terms of treatment for rheumatologists.
By Route of Administration, Injectable Segment Leads the Psoriatic arthritis treatment Market
The injectable segment dominated the psoriatic arthritis treatment market with a 42.13%, as biologics drugs were widely received and most of them are given by injection in subcutaneous or intravenous form. Injectables provide fast and targeted relief from moderate-to-severe conditions and have become the treatment of choice for patients and prescribers. Their high bioavailability, possibility of self-administration using self-injectors or autoinjector pens, and long dosing intervals are factors that contribute to improving patient adherence to treatment.
By Distribution Channel, the Hospital Pharmacies segment led the Psoriatic arthritis treatment Market
The hospital pharmacies segment dominated the psoriatic arthritis treatment market as the high prescribing and administration rates of the biologics demand close medical monitoring. Years of inpatient experience, infusion, and payer consolidation have given hospitals an edge as convenient gateways for specialty care that deliver high-margin/large-ticket therapies.
For a Personalized Briefing with Our Industry Analysts, Connect Now: https://www.snsinsider.com/request-analyst/3223
Psoriatic arthritis treatment Market Dominated by North America, Asia Pacific to Register Fastest Growth
North America holds the highest share in the psoriatic arthritis treatment market with a 39.46% market share in 2023, owing to well-established healthcare facilities, key players’ presence, and high utilization of targeted and biologic therapies. Market growth is underpinned by strong patient and physician awareness and broad reimbursement coverage. Additionally, the strong clinical research efforts and early regulatory approval, especially in the U.S., have resulted in the largest share of the North American psoriatic arthritis treatment market in the U.S. alone.
The Asia Pacific is projected to grow at the highest CAGR during the forecast period due to the growing patient population, developing healthcare infrastructure, and improving access to specialty medication. Increasing awareness, healthcare spending, and government support in countries such as China, India, and Japan are boosting diagnosis and treatment rates.
Key Psoriatic Arthritis Treatment Companies Profiled in the Report
- AbbVie (Humira, Rinvoq)
- Amgen (Enbrel, Aimovig)
- Johnson & Johnson (Stelara, Tremfya)
- Novartis (Cosentyx, Kisqali)
- Merck & Co. (Remicade, Jemperli)
- Pfizer (Xeljanz, Enbrel)
- Bristol-Myers Squibb (Orencia, Otezla)
- Eli Lilly and Company (Taltz, Olumiant)
- Sanofi (Kevzara, Dupixent)
- Gilead Sciences (Biktarvy, Veklury)
- UCB Pharma (Cimzia, Kusabri)
- Abbott Laboratories (Humira, Simulect)
- Horizon Therapeutics (Tepezza, Krystexxa)
- Boehringer Ingelheim (Olumiant, Actemra)
- Roche (Actemra, Venclexta)
- Celltrion Healthcare (Remsima, Truxima)
- Mylan (Renflexis, Biosimilars in Development)
- Teva Pharmaceutical Industries (Copaxone, Ajovy)
- Samsung Biologics (Renflexis, Biosimilars Pipeline)
- AstraZeneca (Fasenra, Imfinzi)
Psoriatic Arthritis Treatment Market Segmentation
By Drugs Class
- NSAIDs
- DMARDs
- Biologics
- Others
By Route of Administration
- Topical
- Oral
- Injectable
By Distribution Channel
- Hospital Pharmacies
- Online Pharmacies
- Retail Pharmacies
Psoriatic Arthritis Treatment Market Report Scope
| Report Attributes | Details |
| Market Size in 2023 | US$ 11.08 billion |
| Market Size by 2032 | US$ 25.41 billion |
| CAGR | CAGR of 9.70% From 2024 to 2032 |
| Base Year | 2023 |
| Forecast Period | 2024-2032 |
| Historical Data | 2020-2022 |
| Regional Analysis | North America (US, Canada, Mexico), Europe (Germany, France, UK, Italy, Spain, Poland, Turkey, Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America) |
| Key Growth Drivers |
|
Buy the Full Psoriatic Arthritis Treatment Market Report (Single-User License) Now: https://www.snsinsider.com/checkout/3223
Table of Contents – Major Key Points
1. Introduction
2. Executive Summary
3. Research Methodology
4. Market Dynamics Impact Analysis
5. Statistical Insights and Trends Reporting
5.1 Incidence and Prevalence (2023)
5.2 Prescription Trends (2023) by Region
5.3 Healthcare Spending (by Region) (2023)
5.4 Trends in Drug Development and Approvals
5.5 Patient Demographics and Treatment Adherence
6. Competitive Landscape
7. Psoriatic Arthritis Treatment Market by Drugs Class
8. Psoriatic Arthritis Treatment Market by Route of Administration
9. Psoriatic Arthritis Treatment Market by Distribution Channel
10. Regional Analysis
11. Company Profiles
12. Use Cases and Best Practices
13. Conclusion
About Us:
SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.
